Business Context and Reporting Period
This Form 8-K Current Report was filed by Lifecore Biomedical, Inc. (formerly Landec Corporation) on November 14, 2022. The filing documents a corporate name change and the associated amendment to the Company's Certificate of Incorporation and Bylaws, effective November 14, 2022.
Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report is strictly administrative regarding corporate governance and securities trading details.
Material Changes
- Corporate Name: Changed from "Landec Corporation" to "Lifecore Biomedical, Inc."
- Trading Symbol: Changed from "LNDC" to "LFCR" on The NASDAQ Global Select Market, effective November 15, 2022.
- Corporate Documents: Amendments to the Certificate of Incorporation and Bylaws were executed to reflect the name change.
- Security Identification: The CUSIP number for the common stock remains unchanged.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, outlook, or management commentary on future performance. It notes that the name change did not require stockholder approval and will not affect the rights of security holders. A press release announcing the change was issued on November 14, 2022, but is not deemed "filed" for liability purposes under Section 18 of the Exchange Act.
Key Facts for Investor Verification
- Verify the new trading symbol "LFCR" on The NASDAQ Global Select Market starting November 15, 2022.
- Confirm that the CUSIP number remains unchanged despite the name and symbol change.
- Review the attached exhibits (3.1 and 3.2) for the full text of the Charter and Bylaws amendments.
- Note that this filing contains no financial performance data; refer to the most recent 10-K or 10-Q for financial metrics.